Trial Profile

A study of the safety, absorption and effects of investigational drug ARV-102 in patients with Parkinson's disease

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 08 May 2025

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ARV 102 (Primary)
Indications Parkinson's disease
Focus Adverse reactions
Sponsors Arvinas

Most Recent Events

01 May 2025 According to an Arvinas media release, company to initiate the MAD cohort of the Phase 1 clinical trial in patients with Parkinson's disease (2H 2025).
01 May 2025 According to an Arvinas media release, company to continue enrollment and present initial data from the SAD cohort of the ongoing Phase 1 clinical trial in patients with Parkinson's disease (2H 2025).
16 Feb 2025 New trial record

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com